Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupi Xiaoji oral liquid plus basic treatment for pediatric mesenteric lymphadenitis
ChiCTR2300072910Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- May 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of bupi xiaoji oral liquid in mesenteric lymphadenitis (2 arms), sponsored by Xijing Hospital. Primary endpoints: Proportion of patients with ≥50% decrease in abdominal pain score at 30 minutes after randomization, Time to disappearance of abdominal pain and 1 more. Planned start May 2023; status: not yet recruiting.
02
Drugs
bupi xiaoji oral liquid
03
Conditions
mesenteric lymphadenitis
Beyond the preview
Go deeper on ChiCTR2300072910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072910.